# Immunophotonics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immunophotonics

- Industry: Pharmaceuticals
- Headquarters: St. Louis, US
- Website: www.immunophotonics.com
- Total disclosed funding: $24M
- Latest round: Series B (Apr 6, 2022)
- Investors on record: 10

## About

Based in Missouri, US, and founded in 2012, Immunophotonics, Inc. provides a carbohydrate polymer that can turn cancer hypnosis into the removal of tumors. As of 2023, the company is headed by its CEO Lu Alleruzzo, who co-founded the firm along with Thomas Hode. In April 2022, the firm raised USD 21.4 million in Series B funding co-led by investors Zubizoom Investments and ROVAQ Ventures, with participation from returning investors Immune, LLC and iSelect Fund Management.

The company offers situ autologous (therapeutic) cancer vaccines (inCVAX) for the treatment of metastatic cancers. Following a tumor ablation, the company's chemical is administered intratumorally, utilizing the full spectrum of tumor-associated neoantigens that are present in situ for the immune system following ablation-based immunogenic cell death.

## Funding rounds

- Series B, Apr 6, 2022, $21M — iSelect Fund Management, Zubizoom Investments, ROVAQ Ventures, Immune, LLC
- Series B, Aug 24, 2020 — Argonautic Ventures
- Series A, Feb 3, 2018 — Argonautic Ventures
- Series A, Jan 26, 2015, $0.6M — BioGenerator, Missouri Technology Corporation, Cultivation Capital, St. Louis Arch Angels, Billiken Angels Network, iSelect Fund Management
- Series A, Jun 12, 2014, $1.6M — BioGenerator, Missouri Technology Corporation, Cultivation Capital, St. Louis Arch Angels, Billiken Angels Network

## Investors

- BioGenerator (https://capitalatlas.ai/funds/biogenerator) — Series A
- Missouri Technology Corporation — Series A
- Cultivation Capital (https://capitalatlas.ai/funds/cultivation-capital) — Series A
- St. Louis Arch Angels — Series A
- Billiken Angels Network — Series A
- iSelect Fund Management (https://capitalatlas.ai/funds/iselect-fund-management) — Series A, Series B
- Argonautic Ventures (https://capitalatlas.ai/funds/argonautic-ventures) — Series A, Series B
- Zubizoom Investments — Series B
- ROVAQ Ventures (https://capitalatlas.ai/funds/rovaq-ventures) — Series B
- Immune, LLC — Series B